2:00 p.m. ET Fed Decision: On Hold? The Real Trade Is Warsh’s Tone — Top Beneficiary Stocks in Three Scenarios
2026/10/28 03:34🔥 US Stock Hotspot Radar is Live! Content: 3 major themes + 6 selected stocks + 7 key events. Where are this week’s opportunities? Click the link to see all 22 trading directions in one chart →
I. Rates Likely on Hold — The Press Conference Is the Real Focus
The Federal Reserve’s target range for the federal funds rate currently stands at 3.75%–4.00%. Markets widely expect the October 28 decision (2:00 p.m. ET) to leave the upper bound at 4.00% unchanged (CME FedWatch shows a >90% probability of a hold).
September CPI rose to 3.7% year-over-year (core at 2.6%), with energy prices significantly pushing up inflation, while the labor market remains broadly stable and the unemployment rate sits around 4.2%.
Since taking office, Kevin Warsh has emphasized data dependence and reduced forward guidance. In September, the Fed delivered its first 25bp rate hike in three years.
This meeting has no Summary of Economic Projections. The real focus will be on the wording of the policy statement and the tone of Warsh’s press conference at 2:30 p.m. ET, especially any signals regarding a possible further hike in December.
II. Three Scenarios — Beneficiary Stocks Clearly Differentiated
| Base Case | Rates on hold, statement neutral-to-hawkish, signals possible further hike in December | JPM, BAC, GS; XOM, COP; GE | Banks benefit from net interest margin expansion; energy benefits from economic resilience and oil prices; industrials relatively resilient |
| Hawkish Surprise | Unexpected hike or clearly more hawkish language, explicit signals of more hikes | JPM, BAC, XOM, GS | Higher rates directly boost bank profitability; strong economy supports energy and industrials; growth stocks face short-term pressure |
| Dovish Surprise | Rates on hold but tone softens, downplays further hikes | NVDA, AMD, META, AMZN, TSLA, AVGO; PLTR, HOOD | High-valuation growth and AI names are rate-sensitive; lower discount rates support valuation recovery; sentiment-driven upside |
| Neutral / Wait-and-See | Vague language, no clear direction | MSFT, AAPL, UNH, WMT | High-quality large-caps with relatively controlled volatility |
III. The Real Trade Is Warsh’s Tone
Overall, the decision itself is highly likely to be a “hold,” and the real trade is Warsh’s press conference wording and the market’s repricing of the December rate path.
Banks and energy offer better offensive and defensive characteristics in a hawkish environment, while tech and growth depend more on dovish signals. Investors are advised to position in advance according to different scenarios and map out risks, focusing on Warsh’s comments on inflation persistence and the labor market rather than solely on whether rates are hiked.
Position ahead of the event. Wishing you smooth trading.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
